What the new Dysmorphic Disorder Report is saying about the future of treatment


The new Dysmodics Report on the prevalence of the disorder and its associated symptoms has been published in the Lancet Psychiatry journal.

The report, which was produced by the UK’s National Institute for Health and Care Excellence (NICE), looks at the use of medication for treatment of children and adults with a mental health condition.

It is the first report to look at the prevalence and development of a new disorder, known as Bipolar Disorder, which is a complex combination of personality disorders and other conditions.

Its publication in the medical journal is a step in the right direction, as the disorder has a high stigma attached to it and the use and abuse of medication remains a significant issue.

The prevalence of children with a disorder was found to be at its highest in the United Kingdom, where a third of all children diagnosed with the disorder live in poverty.

However, it is the prevalence rates in England and Wales that has been particularly high.

In the UK, there were 7.5 million children and adolescents with Bipolar disorder in 2013, compared to 5.9 million adults.

This means there are more than 8.5 children per 100,000 adults living with a Bipolar diagnosis in the UK.

That number is higher than in the US, where there are about 1.2 children per 1,000 adult residents, and higher than anywhere else in the world.

The researchers also found that children with BMD were more likely to be prescribed medication than adults.

Of the 8,817 children and teens diagnosed with BDD, 7,071 were prescribed an antidepressant.

In addition, a further 1,742 adults had a BMD diagnosis.

Of these, 6,081 had a depressive disorder and 4,865 were prescribed a mood stabiliser.

The authors of the report said this could have an impact on the development of the condition, as many people with BPD are able to cope with symptoms but struggle to manage their symptoms.

“The potential for a negative outcome for children living with BED in the future is likely to result in greater use of non-prescription medication, as well as a significant reduction in the use by adults,” the report concluded.

“It is important to note that the majority of children diagnosed and treated with BUDs do not need to be re-diagnosed or prescribed medication to have a long-term negative impact on their mental health.”

The report also highlighted that children and young people diagnosed with mental health problems are at higher risk of being bullied and isolated, and being subjected to bullying at school.

The findings also highlight the need to develop and fund treatments for mental health disorders, as they can be costly and require a long treatment course.

The National Institute of Mental Health (NIMH) said the report shows the need for greater funding for treatment.

“These are the most expensive mental health conditions in the NHS and, in particular, in terms of mental health treatment,” NIMH spokesperson Andrew Brown said.

“Our mental health funding has been cut in recent years, and it is vital that we continue to invest in mental health research and treatment.

This report shows that there is still a great need for more investment in treatment and research, and that more needs to be done.”